Reinfección por variante Ómicron en pacientes previamente infectados con la variante Delta del coronavirus SARS-CoV-2una realidad cada vez más frecuente en atención primaria (Pag. e35-e36)

  1. N. Sánchez-Varela 1
  2. S. Cinza-Sanjurjo 2
  3. M. Portela-Romero 3
  1. 1 Centro de Saúde Concepción Arenal, Área Sanitaria Santiago de Compostela, Santiago de Compostela, A Coruña, España
  2. 2 Centro de Saúde Porto do Son, Área Sanitaria Santiago de Compostela. Instituto de Investigación Sanitaria de Santiago de Compostela (IDIS), CIBERCV, Santiago de Compostela, A Coruña, España
  3. 3 Centro de Saúde Concepción Arenal, Área Sanitaria Santiago de Compostela, Instituto de Investigación Sanitaria de Santiago de Compostela (IDIS), CIBERCV, Santiago de Compostela, A Coruña, España
Mostrar afiliacións +
Revista:
Semergen: revista española de medicina de familia

ISSN: 1138-3593

Ano de publicación: 2022

Número: 5

Páxinas: 367-367

Tipo: Artigo

DOI: 10.1016/J.SEMERG.2022.01.001 DIALNET GOOGLE SCHOLAR

Outras publicacións en: Semergen: revista española de medicina de familia

Obxectivos de Desenvolvemento Sustentable

Referencias bibliográficas

  • J.R. Pulliam, C. van Schalkwyk, N. Govender, A. von Gottberg, C. Cohen, M.J. Groome, et al. Increased risk of SARS-CoV-2 reinfection associated with emergence of the Omicron variant in South Africa Medrvix (2021), 10.1101/2021.11.11.21266068 View PDFGoogle Scholar
  • C. Holm Hansen, A. Blicher Schelde, I. Rask Moustsen-Helm, H.-D. Emborg, T. Grove Krause, K. Mølbak, et al., on behalf of the Infectious Disease Preparedness Group at Statens Serum Institut Vaccine effectiveness against SARS-CoV-2 infection with the Omicron or Delta variants following a two-dose or booster BNT162b2 or mRNA-1273 vaccination series: A Danish cohort study Medrvix (2021), 10.1101/2021.12.20.21267966 View PDFGoogle Scholar
  • N. Andrews, J. Stowe, F. Kirsebom, S. Toffa, T. Rickeard, E. Gallagher, et al. Effectiveness of COVID-19 vaccines against the Omicron (B.1.1.529) variant of concern Medrvix (2021), 10.1101/2021.12.14.21267615 View PDFGoogle Scholar
  • I. Nemet, L. Kliker, Y. Lustig, N. Zuckerman, O. Erster, C. Cohen, et al. Third BNT162b2 vaccination neutralization of SARS-CoV-2 Omicron infection N Engl J Med. (2021), 10.1056/NEJMc2119358 View PDFGoogle Scholar
  • C. Maslo, R. Friedland, M. Toubkin, A. Laubscher, T. Akaloo, B. Kama Characteristics and outcomes of hospitalized patients in South Africa during the COVID-19 Omicron wave compared with previous waves JAMA. (e2124868) (2021), 10.1001/jama.2021.24868 View PDFGoogle Scholar
  • A. Li, A. Maier, M. Carter, T. Hugh Guan Omicron and S-gene target failure cases in the highest COVID-19 case rate region in Canada — December 2021 J Med Virol. (2021), 10.1002/jmv.27562 View PDFGoogle Scholar
  • E. Mahase Covid-19: Hospital admission 50-70% less likely with omicron than delta, but transmission a major concern BMJ., 375 (2021), p. n3151, 10.1136/bmj.n3151 View PDFView Record in ScopusGoogle Scholar
  • H. Zhao, L. Lu, Z. Peng, L.-L. Chen, X. Meng, C. Zhang, et al. SARS-CoV-2 Omicron variant shows less efficient replication and fusion activity when compared with delta variant in TMPRSS2-expressed cells Emerg Microbes Infect. (2021), pp. 1-18, 10.1080/22221751.2021.2023329 View PDFGoogle Scholar
  • G. Iacobucci Covid-19: GPs are told to postpone routine care to focus on vaccine boosters in response to omicron BMJ., 375 (2021), p. n3083, 10.1136/bmj.n3083 View PDFView Record in ScopusGoogle Scholar
Fonte de datos: Dialnet